Tempus AI (NASDAQ: TEM) signed a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL) for approximately $1.5 billion.
The deal values Personalis at $16.25 per share. This price represents a 6% premium over the previous Friday's closing price. Tempus maintains an option to pay up to 50% of the consideration in cash.
The acquisition builds on a November 2023 partnership and prior investment by Tempus. Tempus currently commercializes the Personalis NeXT Personal minimal residual disease (MRD) test.
The merger integrates Personalis’ MRD technology into the Tempus AI-driven precision oncology platform. The transaction is expected to close in late 2026 or early 2027. Completion remains subject to approval from Personalis shareholders and regulators.